In line with the primary tumor growth, a trend towards increased spleen weight was detectable with anti-CD8α both upon sham and eMSC treatment, but no statistically significant difference was found compared to anti-IgG control spleen weights (Supplementary Figure 11C). The gene discussed is CD8A; the disease is neoplasm.